盟科药业在美国获得临床试验许可；新天药业转让4个药品上市许可｜医药早参

Group 1 - New Tian Pharmaceutical transferred four drug licenses and related production technologies to Guizhou Xinan Tang Group, focusing on core business and optimizing assets [1] - The transferred drugs include "Nai Le Jing Granules," "Nai Le Jing Capsules," "Cold Cough Capsules," and "Regulating Menstruation and Activating Blood Capsules," which are either idle or not yet scaled for sales [1] Group 2 - Watson Bio expects a net profit of 160 million to 190 million yuan for 2025, representing a year-on-year growth of 13% to 34%, driven by a 35% increase in overseas vaccine export revenue [2] - Domestic revenue continues to decline, although at a reduced rate, and non-recurring gains of approximately 80 million yuan significantly contribute to the profit [2] Group 3 - Hanyu Pharmaceutical anticipates a net profit of 40 million to 50 million yuan for 2025, recovering from a loss of 174 million yuan in the previous year, primarily due to significant growth in GLP-1 formulations and raw materials [3] - The CRDMO business is also contributing to revenue, indicating a positive shift in the company's financial performance [3] Group 4 - Amgen Pharmaceutical's MRX-5 tablet received FDA approval to conduct clinical trials in the U.S., targeting non-tuberculous mycobacterial lung disease [4] - This development is a significant advancement in the company's global research pipeline, especially as the drug has orphan drug designation, which may provide market exclusivity if successfully launched [4]